Peripheral Interventions

Leading the market in less-invasive treatments for peripheral vascular disease and cancer.
As the global market leader in peripheral interventions, we offer the broadest portfolio of solutions for treating Peripheral Artery Disease (PAD), Deep Vein Thrombosis (DVT) and cancer. We’re dedicated to developing technologies that improve outcomes, cut costs and—most importantly—save the lives and limbs of more people in more places around the world.

Delivering Meaningful Innovation

Advancing the Treatment of PAD. We’re the only company to offer multiple drug-eluting technologies for treating PAD and received CE Mark approval for the ELUVIA™ Drug-Eluting Vascular Stent System in February 2016. In clinical trials, ELUVIA showed one of the highest patency rates ever reported for a peripheral vascular device. Restoring the Flow. The launch of the AngioJet™ ZelanteDVT™ Thrombectomy Catheter further solidifies our position as the market leader in catheter-based procedures to clear dangerous DVT blood clots. We’re investing in new technologies and education to help advance DVT treatment.

Tumor-Tackling Technologies. We broadened our Interventional Oncology portfolio with the recent acquisition of spherical embolic technologies developed by CeloNova Biosciences, Inc., including the Embozene and Oncozene microspheres. These precisely calibrated spheres are designed to prevent blood flow to the targeted tissue and slow tumor growth.

Conditions We Treat

Peripheral Artery Disease, Deep Vein Thrombosis (DVT), Critical Limb Ischemia, Hypertension, Liver Cancer

Solutions We Offer

Peripheral Balloons and Stents, Drug-Eluting Technologies, Thrombectomy Systems, Atherectomy Devices, Coils and Spherical Embolics
Explore AngioJet™ ZelanteDVT™ Thrombectomy Catheter

Caution: Eluvia Drug-Eluting Vascular Stent System is an investigational device and restricted under U.S. law for investigational use only. Not available for sale in the U.S.


2. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis  Fowkes, F Gerald R et al. The Lancet , Volume 382 , Issue 9901 , 1329 - 1340.

3. Alvaro Alonso, MD, and Lawrence A. Garcia.  The Costs of Critical Limb Ischemia.  Endovascular Today. 2011; Aug: 32-36

4. American Cancer Society. Key Statistics on Liver Cancer. Accessed March 23, 2016.